Notes on the Design of Bioequivalence Study: Lamivudine

Notes on the design of bioequivalence studies with products invited to be submitted to the WHO Prequalification Team – Medicines (PQTm) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below can be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products containing lamivudine.

Pharmacokinetics of lamivudine

Maximum lamivudine concentrations are observed in serum within 0.5 to 3.0 hours of dosing in the fasted state (median Tmax of 1 - 1.5 hour). The half-life of lamivudine is 5-7 hours. Co-administration of lamivudine with food results in a delay of Tmax and a lower Cmax (decreased by 47%). However, the extent (based on the AUC) of lamivudine absorption is not influenced. Therefore, lamivudine can be taken with or without food.

Guidance for the design of bioequivalence studies

Taking into account the pharmacokinetic properties of lamivudine the following guidance with regard to the study design should be taken into account:

**Design:** A cross-over design is recommended.

**Dose:** As the EoI includes lamivudine 150 and 300 mg tablets, the bioequivalence study should be conducted preferably with the 300 mg strength.

For the oral solution or powder for oral solution (50 mg/5ml), the dose of 300 mg should be administered preferably. The bioequivalence study of the oral solution can be waived if the qualitative and quantitative composition of the excipients is similar to that of the comparator, i.e. sucrose 20 % w/v (3 g/15 ml) and propylene glycol. Preservatives (i.e. methyl parahydroxybenzoate and propyl parahydroxybenzoate), buffer agents (i.e. citric acid Anhydrrous and sodium citrate), and flavours (i.e. artificial strawberry flavour and artificial banana flavour) may differ.

**Fasting/fed:** As lamivudine can be taken with or without food, a fasted state study is recommended.

**Subjects:** Healthy adult subjects should be utilized. It is not necessary to include patients in the bioequivalence study.
**Sample size:** Lamivudine $C_{\text{max}}$ seems to be moderately variable (15 - 20% approx.). These data may facilitate the calculation of a sufficient sample size for a cross-over bioequivalence study.

**Washout:** Taking into account the elimination half-life of lamivudine in healthy volunteers of 5-7 hours, a washout period of seven days is considered sufficient to prevent carry over.

**Blood sampling:** The blood sampling should be intensive for the first four hours after administration to properly characterize the $C_{\text{max}}$ of lamivudine. It is not necessary to take blood samples beyond 24 hours for the characterization of lamivudine pharmacokinetics. For example, samples can be taken pre-dose and at 0.25, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00 and 24.00 hours.

**Analytical considerations:** Information currently available indicates that it is possible to measure lamivudine in human plasma using LC-MS/MS analytical methodology. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of the $C_{\text{max}}$ in most profiles of each formulation (test or comparator).

**Parent or metabolite data for assessment of bioequivalence:** The parent drug is considered to best reflect the biopharmaceutical quality of the product. The disposition of lamivudine should be characterized, and the determination of bioequivalence will be based on the parent compound.

**Statistical considerations:** The data for lamivudine should meet the following bioequivalence standards in a single-dose, crossover design study:

- The 90% confidence interval of the relative mean $AUC_{\text{0-t}}$ of the test to reference product should be within 80–125%.

- The 90% confidence interval of the relative mean $C_{\text{max}}$ of the test to reference product should be within 80–125%.